ATE439443T1 - NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON - Google Patents

NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON

Info

Publication number
ATE439443T1
ATE439443T1 AT06752809T AT06752809T ATE439443T1 AT E439443 T1 ATE439443 T1 AT E439443T1 AT 06752809 T AT06752809 T AT 06752809T AT 06752809 T AT06752809 T AT 06752809T AT E439443 T1 ATE439443 T1 AT E439443T1
Authority
AT
Austria
Prior art keywords
peptide derivatives
new
binding protein
disease
disclosed
Prior art date
Application number
AT06752809T
Other languages
English (en)
Inventor
Balu Chakravarthy
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of ATE439443T1 publication Critical patent/ATE439443T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06752809T 2005-06-17 2006-06-16 NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON ATE439443T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69124805P 2005-06-17 2005-06-17
PCT/CA2006/000990 WO2006133566A1 (en) 2005-06-17 2006-06-16 NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE439443T1 true ATE439443T1 (de) 2009-08-15

Family

ID=37531931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06752809T ATE439443T1 (de) 2005-06-17 2006-06-16 NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON

Country Status (7)

Country Link
US (1) US8323925B2 (de)
EP (1) EP1896588B1 (de)
AT (1) ATE439443T1 (de)
CA (1) CA2611054C (de)
DE (1) DE602006008460D1 (de)
ES (1) ES2329511T3 (de)
WO (1) WO2006133566A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803912D0 (en) * 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
GB0804496D0 (en) * 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
PT2646470T (pt) 2010-11-30 2017-05-03 Hoffmann La Roche Anticorpos anti-recetor da transferrina de baixa afinidade e a sua utilização na transferência de scfv terapêuticos através da barreira hematoencefálica
WO2017083700A1 (en) * 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
CA3052058A1 (en) * 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
WO2022093684A1 (en) * 2020-10-30 2022-05-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods of treating inflammatory lung diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
AU2001263006A1 (en) * 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002086122A2 (en) 2001-03-14 2002-10-31 Hybrigenics Protein-protein interactions in adipocytes
AU2003207628A1 (en) * 2002-01-18 2003-09-02 Incyte Corporation Structural and cytoskeleton-associated proteins

Also Published As

Publication number Publication date
US8323925B2 (en) 2012-12-04
EP1896588A1 (de) 2008-03-12
DE602006008460D1 (de) 2009-09-24
ES2329511T3 (es) 2009-11-26
WO2006133566A1 (en) 2006-12-21
EP1896588A4 (de) 2008-08-20
EP1896588B1 (de) 2009-08-12
US20110300141A1 (en) 2011-12-08
CA2611054A1 (en) 2006-12-21
CA2611054C (en) 2017-05-09

Similar Documents

Publication Publication Date Title
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
WO2005123048A3 (en) Screening methods using c-abl, fyn and syk in combination with tau protein
NO20081233L (no) Albumin fusjonsproteiner
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
WO2007137237A3 (en) Treatment of protein misfolding
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
NO20064059L (no) Albumin fusjonsproteiner
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
ATE497508T1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE348632T1 (de) Prion protein peptide und deren verwendung
WO2007044323A3 (en) Fusion proteins for blood-brain barrier delivery
MX2009002816A (es) Proteinas de fusion de albumina.
AR069860A1 (es) Metodo para purificar un anticuerpo cd20
ATE439443T1 (de) NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties